Giovanni Germano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7989415/publications.pdf

Version: 2024-02-01

33	4,552	361413	526287
papers	citations	20 h-index	27 g-index

34	34	34	9513
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CD4 T Cellâ€“Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repairâ€“Deficient Tumors. Cancer Discovery, 2021, 11, 1844-1859.	9.4	37
2	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers, 2021, 13, 2638.	3.7	32
3	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. Cancer Immunology Research, 2021, 9, 825-837.	3.4	6
4	High-dose vitamin C enhances cancer immunotherapy. Science Translational Medicine, 2020, 12, .	12.4	143
5	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Medicine, 2019, 11, 42.	8.2	42
6	SP-0453 Targeting DNA repair to improve immunesurveillance and restrict cancer growth. Radiotherapy and Oncology, 2019, 133, S235-S236.	0.6	0
7	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. Journal of Clinical Oncology, 2019, 37, TPS2659-TPS2659.	1.6	10
8	Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer. , 2019, , .		0
9	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 80-83.	2.3	40
10	Inactivation of DNA repairâ€”prospects for boosting cancer immune surveillance. Genome Medicine, 2018, 10, 91.	8.2	8
11	The Clinical Impact of the Genomic Landscape of Mismatch Repairâ€“Deficient Cancers. Cancer Discovery, 2018, 8, 1518-1528.	9.4	77
12	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nature Medicine, 2018, 24, 961-967.	30.7	244
13	The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2⁺and CCR5⁺IFNÎ³-producing Î³Î´T cells in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L1010-L1025.	2.9	32
14	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. Cancer Research, 2018, 78, 5723-5723.	0.9	5
15	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		0
16	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	27.8	480
17	Abstract PR13: Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth. , 2017, , .		0
18	Abstract 2913: Emergence ofRASorEGFRmutant clones affects duration of response to EGFR blockade in colorectal cancers. , 2017, , .		0

#	Article	IF	Citations
19	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature Communications, 2016, 7, 13665.	12.8	170
20	PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Reports, 2015, 12, 1978-1985.	6.4	163
21	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. Cancer Cell, 2013, 23, 249-262.	16.8	721
22	Trabectedin. OncoImmunology, 2013, 2, e24614.	4.6	49
23	New activities for the anti-tumor agent trabectedin: taking two birds with one stone. Oncotarget, 2013, 4, 496-497.	1.8	9
24	Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. Annals of Medicine, 2011, 43, 581-593.	3.8	19
25	Chemokines in cancer related inflammation. Experimental Cell Research, 2011, 317, 664-673.	2.6	191
26	Cancerâ€promoting tumorâ€associated macrophages: New vistas and open questions. European Journal of Immunology, 2011, 41, 2522-2525.	2.9	179
27	Tumor-Associated Macrophages as Incessant Builders and Destroyers of the Cancer Stroma. Cancers, 2011, 3, 3740-3761.	3.7	73
28	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. Cancer Research, 2010, 70, 2235-2244.	0.9	251
29	Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. Journal of Leukocyte Biology, 2009, 86, 1065-1073.	3.3	1,202
30	Cytokines as a key component of cancer-related inflammation. Cytokine, 2008, 43, 374-379.	3.2	292
31	RaLP, a New Member of the Src Homology and Collagen Family, Regulates Cell Migration and Tumor Growth of Metastatic Melanomas. Cancer Research, 2007, 67, 3064-3073.	0.9	69
32	Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line. Oncology Reports, 2007, 17, 17-23.	2.6	6
33	Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line. Oncology Reports, 0, , .	2.6	1